Inherently radiopaque polymeric products for embolotherapy

Patent metadata

Field	Value
Publication number	US-9770465-B2
Application number	US-201414197679-A
Country	US
Kind code	B2
Filing date	Mar 5, 2014
Priority date	Sep 25, 2003
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.

First claim

What is claimed is:

1. A method for in vivo re-embolizing a blood vessel, said method comprising the steps of:
a) administering an amount of a first embolotherapy product to a blood vessel delivering a supply of blood to or from a targeted tissue, wherein the amount of said first embolotherapy product is effective to form a blockage in said blood vessel; and
b) after said first embolotherapy product has degraded allowing re-access to said blood vessel, subsequently administering an amount of a second embolotherapy product to the same blood vessel, wherein the amount of said second embolotherapy product is effective to form a blockage in said blood vessel again;

wherein said first and second embolotherapy products are independently the same or different, and comprise a particulate formulation comprising polymer particles having a diameter of about 10 microns to about 3,000 microns,
said polymer comprising polymeric units having a structure according to Formula (I):

wherein X=I or Br; Y1 and Y2 independently=0, 1, 2, 3 or 4;
wherein f is between 0 and less than 1, g ranges from 0 to 1, inclusive, and f+g is between 0 and 1, inclusive;
wherein R is independently selected from:

wherein R 1 is independently an alkyl group ranging from 1 to about 18 carbon atoms;

wherein R 2 is independently selected from:

wherein R 1′ is H;
wherein j and m are independently integers from 1 to 8 inclusive;
wherein Z is independently O or S;
wherein A is selected from the group consisting of:

wherein
R 1″ is independently H or an alkyl group ranging from 1 to about 18 carbon atoms, containing from 0 to 5 heteroatoms selected from the group consisting of O and N;
R 3 is a bond or a carbon-containing moiety selected from the group consisting of saturated alkylene, unsaturated alkylene, arylene, and alkylarylene groups, wherein said carbon-containing moiety is substituted or unsubstituted, and contains 1 to about 18 carbon atoms and 0 to 8 heteroatoms selected from the group consisting of O and N; and
B is an aliphatic linear or branched diol, or a poly(alkylene glycol) unit;

and wherein said polymer particles are suspended in a pharmaceutically acceptable liquid.

2. The method of claim 1 , wherein said administering is by injection via a catheter or syringe.

3. The method of claim 1 , wherein said blood vessel comprises varicose and/or spider veins.

4. The method of claim 3 , wherein said administering is by injection via a catheter or syringe.

5. The method of claim 1 , wherein Y1 and Y2 are independently 0, 1 or 2, provided that the sum Y1 +Y2 =1, 2, 3 or 4.

6. The method of claim 1 , wherein B is a poly(C1-C4 alkylene glycol) unit and said units are present in a weight fraction of less than about 25 wt %.

7. The method of claim 6 , wherein B is a poly(ethylene glycol) unit.

8. The method of claim 1 , wherein all X groups are ortho-directed in relation to a phenolic oxygen atom.

9. The method of claim 1 , wherein the value of g ranges from greater than 0.1 to about 0.35.

10. The method of claim 1 , wherein said embolotherapy product comprises polymer particles selected from the group consisting of spherical particles, geometrically non-uniform particles, porous particles, hollow particles, solid particles, and combinations of two or more thereof.

11. The method of claim 1 , wherein said polymer particles further comprise an effective amount of at least one therapeutic agent.

12. The method of claim 11 , wherein said at least one therapeutic agent is selected from the group consisting of a chemotherapeutic agent, a non-steroidal anti-inflammatory, and a steroidal anti-inflammatory.

13. A method for enhancing the local delivery of a therapeutic agent in vivo to a targeted tissue, said method comprising the steps of:
a) administering an amount of an embolotherapy product to a blood vessel through which blood flows to or from said targeted tissue, wherein the amount of said embolotherapy product is effective to form a blockage in said blood vessel;

wherein the embolotherapy product comprises a particulate formulation comprising polymer particles having a diameter of about 10 microns to about 3,000 microns,
said polymer comprising polymeric units having a structure according to Formula (I):

wherein X=I or Br; Y1 and Y2 independently=0, 1, 2, 3 or 4;
wherein f is between 0 and less than 1, g ranges from 0 to 1, inclusive, and f+g is between 0 and 1, inclusive;
wherein R is independently selected from:

wherein R 1 is independently an alkyl group ranging from 1 to about 18 carbon atoms;

wherein R 2 is independently selected from:

wherein R 1′ is H;
wherein j and m are independently integers from 1 to 8 inclusive;
wherein Z is independently O or S;
wherein A is selected from the group consisting of:

wherein
R 1 ″is independently H or an alkyl group ranging from 1 to about 18 carbon atoms, containing from 0 to 5 heteroatoms selected from the group consisting of O and N;
R 3 is a bond or a carbon-containing moiety selected from the group consisting of saturated alkylene, unsaturated alkylene, arylene, and alkylarylene groups, wherein said carbon-containing moiety is substituted or unsubstituted, and contains 1 to about 18 carbon atoms and 0 to 8 heteroatoms selected from the group consisting of O and N; and
B is an aliphatic linear or branched diol, or a poly(alkylene glycol) unit;

and wherein said polymer particles are suspended in a pharmaceutically acceptable liquid;
b) simultaneously administering a therapeutic agent with step a),
or
separately locally administering a therapeutic agent to said targeted tissue,
wherein contact of the therapeutic agent is restricted to said targeted tissue,
wherein said therapeutic agent is selected from the group consisting of chemotherapeutic agents, non-steroidal anti-inflammatory agents, and steroidal anti-inflammatory agents; and
c) after said embolotherapy product has degraded allowing re-access to said blood vessel, repeating steps a) and b).

14. The method of claim 13 , wherein said administering is by injection via a catheter or syringe.

15. The method of claim 13 , wherein said blood vessel comprises varicose and/or spider veins.

16. The method of claim 15 , wherein said administering is by injection via a catheter or syringe.

17. The method of claim 13 , wherein Y1 and Y2 are independently 0, 1 or 2, provided that the sum Y1 +Y2 =1, 2, 3 or 4.

18. The method of claim 13 , wherein B is

Assignees

• Univ Rutgers

Inventors

• Brandom Don K
• Schmid Eric
• Zeltinger Joan
• Bolikal Durgadas
• Kohn Joachim B

Classifications

• A61K31/785 Primary

  Polymers containing nitrogen · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K49/0442

  Polymeric X-ray contrast-enhancing agent comprising a halogenated group · CPC title